CellVantage™-AAV
CellVantage™-AAV is a powerful media additive designed to significantly improve Adeno-Associated Virus (AAV) production efficiency, enabling higher yields without altering your existing workflow.
Compatible with various AAV serotypes, HEK-based cell lines and PEI transfection reagents, CellVantage™-AAV helps you generate high-titer AAV preparations more efficiently to accelerate research and development.
| Specifications | |
|---|---|
| Cell Line | Optimal for HEK293s (VPC 2.0) |
| Application | AAV Production |
| Transfection Reagents | Optimal for PEI-based |
| Culture Type | Suspension/ Adherent |
| Appearance | White Powder |
| Active Compound | VSE-007 |
| Stability | 12 months |
| Storage | 20 ± 5ºC, protect from light |
This depends on the application and should be optimized. Please consult with Virica for application specific guidance.
No, the compounds can remain in the media for the duration of viral production.
Compounds are stable in their appropriate solvent at -80°C for one year. Stability in aqueous solutions (i.e cell culture medium) is compound and context-dependent and should be determined on a case-by-case basis. Please consult with Virica for further guidance.
Research grade VSE powders are not routinely tested for sterility. The VSEs should be resuspended using sterile diluents in a sterile environment. Sterile filtration is not recommended when testing dose ranges during small-scale formulation development. If absolutely necessary, please consult with Virica for recommended filter types before proceeding.
VSE application time is platform dependent. Virica will provide platform specific guidance prior to project initiation.
Benefits
- Up to 5x increase in AAV genomic titer (vg/mL)
- Robust yield enhancement across multiple AAV serotypes
- Simple media additive that is easy to incorporate
- Accelerates AAV viral vector-based therapeutic pipeline development
- Reduces production costs
- Improves scalability
